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ABSTRACT 
 
High red meat intake is associated with increased colorectal cancer (CRC) risk, while 
resistant starch is probably protective. Resistant starch fermentation produces butyrate, which 
can alter microRNA (miRNA) levels in CRC cells in vitro; effects of red meat and resistant 
starch on miRNA expression in vivo were unknown. This study examined whether a high red 
meat (HRM) diet altered miRNA expression in rectal mucosa tissue of healthy volunteers, 
and if supplementation with butyrylated resistant starch (HRM+HAMSB) modified this 
response. In a randomised cross-over design, twenty-three volunteers undertook four 4-week 
dietary interventions; an HRM diet (300 g/day lean red meat) and an HRM+HAMSB diet 
(HRM with 40 g/day butyrylated high amylose maize starch), preceded by an entry diet and 
separated by a washout. Faecal butyrate increased with the HRM+HAMSB diet. Levels of 
oncogenic mature miRNAs, including miR-17-92 cluster miRNAs and miR-21, increased in 
the rectal mucosa with the HRM diet, while the HRM+HAMSB diet restored miR-17-92 
miRNAs, but not miR-21, to baseline levels. Elevated miR-17-92 and miR-21 in the HRM 
diet corresponded with increased cell proliferation, and a decrease in miR-17-92 target gene 
transcript levels, including CDKN1A. The oncogenic miR-17-92 cluster is differentially 
regulated by dietary factors that increase or decrease risk for CRC, and this may explain, at 
least in part, the respective risk profiles of high red meat and resistant starch. These findings 
support increased resistant starch consumption as a means of reducing risk associated with an 
HRM diet. 
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INTRODUCTION 
 
The majority of colorectal cancers (CRCs) occur sporadically, with development influenced 
by environmental and lifestyle factors, including diet (1). Systematic reviews of cohort and 
case-control studies have found high red meat or processed meat intake to be a convincing 
risk factor (1, 2), with intake of more than 500 g of cooked red meat per week significantly 
increasing CRC risk (1). Plausible mechanisms include inducing DNA strand breaks and 
enhancing pro-mutagenic DNA adduct formation (3, 4). High red meat consumption has also 
been linked to gut microbiome changes and inflammation (5, 6). In contrast, dietary fibre 
probably protects against CRC, with systematic review evidence identifying a dose-response 
relationship, with 10% decreased risk per 10 g fibre intake per day (1). Interventional studies 
provide less conclusive evidence, and longer-term trials and higher fibre levels may be 
needed to reproduce effects from observational studies (7).  
 
One protective mechanism for fibre is the production of fermentation products, particularly 
the short-chain fatty acid (SCFA) butyrate (1). Butyrate is a histone deacetylase inhibitor, 
with anti-tumorigenic effects (8-12). Aberrant microRNA (miRNA) expression contributes to 
CRC development (13-15), with miRNAs such as miR-21 and the miR-17-92 cluster of 
miRNAs often increased in CRCs and possessing oncogenic properties (16, 17). We have 
shown that butyrate can modulate miRNA expression in CRC cells in vitro (18). The miR-17-
92 cluster, comprising miR-17, miR-18a, miR-19a, miR-20a, miR-19b, and miR-92a, was 
significantly decreased with butyrate. This decrease may be partially responsible for the anti-
proliferative effects of butyrate, with addition of miR-17-92 mimics reversing this and 
increasing proliferation; miR-19a and b in particular were key promoters of proliferation 
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(18). Through epigenetic mechanisms, butyrate may be able to reverse the miRNA 
dysregulation observed in CRC (18).  
 
Higher colonic butyrate levels can be achieved with resistant starch supplementation 
compared with other fibre sources (19). Resistant starch can also be acetylated with butyrate; 
butyrylated high amylose maize starch (HAMSB) can deliver esterified butyrate to the human 
colon, leading to increased faecal butyrate compared with standard high amylose maize 
starch (P < 0.0001) (20, 21). In rodents, resistant starch supplementation to a high red meat 
diet increased colonic butyrate, altered gut microbiota, decreased inflammation, and 
attenuated red meat-induced DNA damage (3, 5, 22). HAMSB was more effective than 
standard amylose maize starch in lowering genetic damage (23). One human trial has 
suggested inconclusively that fibre may modify DNA adduct formation in the context of high 
red meat consumption (4); however, to date no other human trials have examined the 
combined effects of red meat and resistant starch. There has been no previous examination in 
vivo of the effects of these substances on miRNA expression in colorectal cells.  
 
This human trial aimed to determine if consumption of a diet high in lean red meat altered 
miRNA expression in rectal mucosa tissue, and if supplementation with resistant starch could 
protect against this dysregulation by increasing butyrate levels in the colorectum. In a 
randomised cross-over design, markers of CRC risk were measured in healthy human 
volunteers who undertook two four-week intervention diets, a high red meat (HRM) diet, and 
a high red meat diet supplemented with butyrylated resistant starch (HRM+HAMSB) 
(StarPlus™, National Starch and Food Innovation, Bridgewater, NJ). It was hypothesised that 
regulation of miRNA expression may partially explain some of the chemo-protective effects 
of resistant starch and the increased CRC risk associated with high red meat intake. 
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MATERIALS AND METHODS 
 
Subjects 
The randomised, controlled cross-over trial was approved by the Flinders Clinical Research 
Ethics Committee and Clinical Drug Trials Committee, and registered with the Australian 
New Zealand Clinical Trials Registry (ACTRN12609000306213). Sample size was based on 
the anticipated effect on a primary outcome (fermentation products). A group size of n = 20 
gave 80% power to detect a 20% change with 95% probability. Twenty-five were recruited to 
allow for drop-outs. A computer-generated randomisation sequence was implemented by a 
trial nurse, to determine which intervention diet was received first. Due to the nature of the 
interventions, participants were not blinded. Healthy volunteers aged 50 – 75 years, with no 
active bowel disease, and able to provide informed consent were eligible for inclusion. 
Exclusion criteria included evidence of active bowel disease or malabsorption, intolerance to 
high-fibre foods, perceived contraindication to consumption of the high protein diet, previous 
bowel surgery (excluding polypectomy), ingestion of regular laxatives or probiotic 
complimentary medicines, and antibiotic therapy in the previous four weeks. Patients were 
recruited by advertisement or invitation from their physician at the Flinders Medical Centre 
gastroenterology outpatient clinics, and written informed consent was obtained. Participants 
could withdraw at any time.  
 
Study design 
Dietary interventions were explained during clinic visits. The study consisted of two 
intervention periods of four weeks each, preceded by a four-week run-in (entry) period and 
separated by a four-week washout period. Volunteers were randomised to an HRM diet (300 
g raw weight of lean red meat per day) or HRM+HAMSB diet (300 g raw weight of lean red 
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meat per day with 40 g of butyrylated high amylose maize starch per day [StarPlus™, which 
is 50 – 60% resistant starch](24)). Volunteers received the alternative diet for the second 
intervention. Meat was supplied in frozen packs of lean mince, beef strips, or lamb strips. 
HAMSB was supplied as pre-packed 20 g sachets, with two to be consumed daily by mixing 
into 250 mL reduced fat milk or orange juice. During the HRM diet, participants were also 
required to consume two serves of reduced fat milk or orange juice per day, to match the 
HRM+HAMSB diet. The level of red meat used is tolerated well, with studies often using 
400 g of red meat per day (4). Intervention studies have shown that 40 g per day of 
butyrylated resistant starch significantly raises colonic butyrate concentrations (21). 
Participants were to maintain their usual diet during the study but to avoid additional high-
protein, fibre or probiotic supplements, and any medication that could interfere with bowel 
function. Participants were monitored by a trial nurse and dietitian, to ensure intervention 
guidelines were followed, and weight was kept stable.  
 
Sample collection and analysis 
The effects of the dietary interventions on colonic fermentation product formation and on 
epithelial consequences were examined as primary outcomes. SCFA were measured from 
faecal samples, and miRNA expression changes, target gene levels, and cell proliferation 
were measured from rectal mucosa samples. Faecal and rectal pinch biopsy specimens were 
obtained at the end of each four-week dietary period. Details of medical history and 
medications, weight, bowel health, and adverse events were collected throughout the study. 
Composition of the participants’ diets and compliance with the interventions was assessed 
using weighed food diaries, completed by participants for the last three days of each four-
week dietary period. Food diaries were entered into Foodworks Professional 7 nutritional 
calculation software (Xyris Software, Kenmore Hills, QLD, Australia) by a dietitian, to 
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calculate energy and macronutrient intake based on Australian food composition tables and 
food manufacturers’ data. 
 
Faecal collection was conducted by participants for the last 24 h of each dietary period. 
Samples were homogenized in three volumes of internal standard solution (1.68 mmol 
heptanoic acid/L) and centrifuged. The supernatant was vacuum distilled, and 0.2 µL of each 
distillate was loaded onto a Zebron ZB-FFAP gas chromatography (GC) column 
(Phenomenex, Torrance, CA) within an Agilent 6890N Network GC system (Agilent, Santa 
Clara, CA). Concentrations of acetate, butyrate, propionate, and total SCFAs were reported. 
 
Participants undertook anal examination by an experienced gastroenterologist at the end of 
each dietary period, and four pinch rectal biopsies were taken with forceps through 
sigmoidoscopic examination performed without bowel preparation. Two biopsies of <0.5 cm 
in any dimension were stored in RNAlater (Ambion, Foster City, CA). Additional biopsies 
were formalin-fixed. Biopsies stored in RNAlater were used for quantitation of miRNA and 
target gene mRNA levels. Each biopsy was homogenised in 0.5 mL TRIzol Reagent 
(Ambion, Foster City, CA), and total RNA extracted according to the manufacturer’s 
instructions. RNA was quantified using a Nanodrop-8000 spectrophotometer (Nanodrop 
Technologies, Wilmington, DE).  
 
miRNA expression analysis was conducted by relative quantitation real-time RT-PCR using 
TaqMan miRNA assays (Applied Biosystems, Foster City, CA). cDNA was synthesized from 
20 ng total RNA using miRNA-specific primers, and real-time PCR was carried out using 
triplicate 10 µl reactions for each biological replicate including 1 µl of reverse transcription 
product, 0.5 µl miRNA-specific primer, and probe assay mix, and 1 × TaqMan Universal 
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PCR Master Mix No AmpErase UNG (Applied Biosystems) (assay IDs: miR-17: 000393, 
miR-18a: 002422, miR-19a: 000395, miR-20a: 000580, miR-19b: 000396, miR-92a: 000430, 
miR-16: 000391, miR-21: 000397). Results were normalized relative to the endogenous small 
nuclear RNA gene RNU6B (assay ID: 001093) using Qgene (25). For mRNA expression 
analysis, real-time RT-PCR was conducted using TaqMan Gene Expression assays (Applied 
Biosystems). cDNA was synthesized from 0.6 µg total RNA using M-MLV Reverse 
Transcriptase, RNase H minus (Promega, Madison, WI) and random hexamer primers. Real-
time PCR was carried out using triplicate 10 µl reactions including 2 µl of RT product, 0.5 µl 
mRNA-specific Gene Expression assay mix, and 1× TaqMan Gene Expression master mix 
(Applied Biosystems) (assay IDs: CDKN1A: Hs00355782_m1, PTEN: Hs02621230_s1, 
BCL2L11: Hs00708019_s1). Results were normalized relative to endogenous controls ACTB 
(β-actin) (assay ID: Hs99999903_m1) and B2M (β-2-microglobulin) (assay ID: 
Hs00984230_m1) using QbasePlus (Biogazelle, Zwijnaarde, Belgium).  
 
To assess the proliferative activity and distribution of proliferating cells in the colonic crypts, 
the proliferating cell nuclear antigen (PCNA) assay was performed using standard 
immunohistochemical procedures (11). Deparaffinised rectal biopsy sections were rehydrated 
in a graded series of ethanol from 100 to 50% and then distilled water. Primary mouse 
monoclonal antibody (PC10) (Santa Cruz Biotechnology, Santa Cruz, CA) was placed on 
slides (1:500 dilution) and incubated overnight, followed by incubations with a murine ultra 
streptavidin HRP detection kit (Covance Laboratories, Madison, WI). Visualisation was 
performed using 3,3’-diaminobenzidine (DAB) chromagen and substrate buffer (Covance 
Laboratories), with slides counterstained with haematoxylin. PCNA-positive cells were 
identified in 20 randomly chosen intact crypts by an independent observer who was blinded 
to the treatment groups. 
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Statistical analysis 
Data were presented as mean ± standard error of the mean (SEM), with graphs prepared using 
GraphPad Prism 6 (GraphPad Software Inc, La Jolla, CA). Statistical analyses were 
performed in IBM SPSS Statistics 22 (IBM SPSS Inc, Chicago, IL) using the repeated 
measures general linear model, with statistical significance for paired comparisons obtained 
using Sidak multiple comparisons test. For each variable, data were assessed for carry-over 
and period effects. For variables with no significant carry-over or period effects, data from 
both intervention periods were combined and the repeated measures analysis was used. 
Secondary analyses were performed for outcomes where there was a significant effect of 
treatment order, with the group that consumed the HRM diet first analysed independently 
from the group that consumed the HRM+HAMSB diet first. An adjusted P value < 0.05 was 
considered significant.
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RESULTS 
 
Demographic data and dietary intake 
Recruitment commenced in July 2009, with participants followed-up for the four month 
duration of the interventions. Data collection was completed by September 2010. Twenty-
five participants were randomly assigned, with 12 allocated to the HRM dietary intervention 
first, and 13 allocated to the HRM+HAMSB dietary intervention first (Figure 1). Two 
participants withdrew prior to commencing the interventions; one due to unrelated medical 
problems, and one due to intolerance of the first rectal biopsy. At study completion, 23 
participants had received both intervention diets (17 males and 6 females, aged 50 – 75 
years), and data from these participants were analysed. There were no major complications, 
and all 23 volunteers tolerated sample collection and the interventions, except one volunteer 
who usually had a vegetarian diet and found 300 g red meat per day difficult to tolerate. 
Approximately one third of volunteers reported increased flatulence on trial diets; it was 
unclear whether this could be linked to increased red meat or resistant starch intake. 
Participants maintained consistent body weight (mean of 80 kg after each diet; P > 0.05). 
Weighed food diaries showed that compared with the entry diet, protein intake was 
significantly increased in the HRM diet (P < 0.0001) and in the HRM+HAMSB diet (P = 
0.001); intake was similar in the HRM and HRM+HAMSB diets (P = 0.33). Fibre and starch 
intake were decreased in the HRM diet compared with the entry (P < 0.0001 and P = 0.02 
respectively) and HRM+HAMSB diets (P < 0.0001 and P = 0.02 respectively). 
 
Faecal SCFA levels 
There was a significant increase in acetate (P = 0.002), propionate (P = 0.0006), butyrate (P = 
0.005), and total SCFA (P = 0.0008) in faecal samples for the HRM+HAMSB diet compared 
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with the entry diet, and a significant increase in propionate (P = 0.02) and butyrate (P = 0.04) 
for the HRM+HAMSB diet compared with the HRM diet (Figure 2). There was no 
significant difference between the entry and HRM diets for any of the SCFAs measured (P > 
0.05), and between the entry and washout diets for any of the SCFAs measured (P > 0.05). 
 
miRNA expression changes 
miR-17-92 cluster miRNA levels were examined in the rectal biopsy specimens, as these 
were altered with butyrate treatment in previous studies in vitro (18). Two miRNAs that were 
not altered by butyrate in vitro were examined for comparison (18);  miR-21, an oncogenic 
miRNA, and miR-16, a miRNA that is generally abundantly and ubiquitously expressed in 
normal tissue (26). Levels of miR-17-92 cluster miRNAs increased with the HRM diet 
compared with the entry diet, but not with the HRM+HAMSB diet. The increased expression 
of miRNAs within the miR-17-92 cluster with the HRM diet versus the entry diet was 
significant for miR-19a (P = 0.04) and miR-19b (P = 0.007), and approaching significance for 
miR-20a (P = 0.08) (Figure 3A). This rise in miR-17-92 miRNA levels with the HRM diet 
alone was approximately 30% (Figure 3B). Conversely, in the HRM+HAMSB diet, the miR-
17-92 cluster miRNA levels were lower than with the HRM diet alone (approximately 20%), 
which was significant for miR-17 (P = 0.005), miR-19a (P = 0.04), miR-20a (P = 0.003), 
miR-19b (P = 0.02), and miR-92a (P = 0.02). There was no significant difference between the 
entry and HRM+HAMSB diet for any of the miR-17-92 cluster miRNAs (P > 0.05), and no 
significant difference between the entry and washout diets for any of the miR-17-92 miRNAs 
(P > 0.05). miR-16 appeared stably expressed regardless of the intervention (P > 0.05 for all 
comparisons) (Figure 3C). There was a significant increase in miR-21 with the HRM diet 
compared with the entry diet (P = 0.03), and a trend towards an increase with the 
HRM+HAMSB compared with the entry diet (P > 0.05) (Figure 3C). There was no 
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significant difference between the HRM and HRM+HAMSB diets for miR-21 (P > 0.05); 
thus high red meat appeared to alter miR-21 levels, but resistant starch supplementation had 
little protective effect. 
 
miR-17-92 target gene changes 
miR-17-92 cluster miRNAs target genes that are important in cell cycle control, including the 
cell cycle inhibitor CDKN1A (target of miRs 17 and 20a) and the pro-apoptotic genes PTEN 
(target of miRs 17, 19a, 19b, and 20a) and BCL2L11 (target of miRs 17, 18a, 20a, and 92a) 
(27-30). The influence of the diet-induced changes in miR-17-92 cluster miRNA levels on 
these target genes was investigated in the rectal biopsy samples. There was a trend towards 
decreased CDKN1A, PTEN and BCL2L11 mRNA levels with the HRM diet compared with 
the entry diet, which was statistically significant for CDKN1A (P = 0.04) (Figure 4A). For 
PTEN and BCL2L11, the HRM+HAMSB diet was not significantly different from the entry 
diet (P > 0.05) or HRM diet (P > 0.05); for CDKN1A there appeared to be decreased mRNA 
levels with the HRM+HAMSB diet compared with the entry diet (P = 0.02). CDKN1A and 
BCL2L11 mRNA levels appeared lower with the washout diet than with the entry diet; 
however, this was not statistically significant (P > 0.05) 
 
Cell Proliferation 
A PCNA assay was used as a proliferation marker in the fixed rectal biopsies. The HRM diet 
increased proliferation compared with the entry diet (P = 0.02) (Figure 4B). Proliferation with 
the HRM+HAMSB diet appeared intermediate between the HRM diet and the entry diet, and 
not significantly different from either the entry diet (P > 0.05) or HRM diet (P > 0.05). 
Proliferation with the washout diet was significantly higher than with the entry diet (P = 
0.02). There was a significant effect of treatment order; consuming the HRM diet first 
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produced significantly higher proliferation compared with consumption of the 
HRM+HAMSB diet first (P = 0.04), and compared with consumption of the HRM diet as the 
second treatment (P < 0.01) (Figure 4C). 
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DISCUSSION 
 
This randomised cross-over trial is the first to examine the effects of an HRM diet and 
butyrylated resistant starch supplementation on miRNA expression in rectal mucosa of 
healthy volunteers. In a novel finding, high red meat intake was shown to alter miRNA levels 
in rectal mucosa tissue, while HAMSB could mitigate some of these changes. High red meat 
intake significantly increased rectal mucosa levels of miR-17-92 cluster miRNAs and miR-
21, which are both elevated in CRC (16, 17). The miR-17-92 cluster has been designated 
oncomir-1 (31), and can promote proliferation and angiogenesis, inhibit differentiation, and 
sustain cell survival (29, 30). Elevated miR-17-92 levels have been associated with invasion 
and metastasis of CRC cells (32), and poorer survival (33). miR-19a and b in particular are 
key oncogenic determinants (29, 30), and both were significantly elevated with the HRM diet 
compared with the entry diet. miR-21 has similarly been classed as oncogenic, and can also 
induce tumourigenesis, invasion and metastasis (34-36). Elevated miR-21 in CRC has been 
linked to poorer survival and therapeutic outcomes (37). 
 
Although HRM intake increases CRC risk, butyrylated resistant starch can potentially 
ameliorate some of these effects. Rodent studies have shown that resistant starch can raise 
colonic butyrate levels, alter gut microbiota abundance, reduce adenocarcinoma formation in 
response to a carcinogen, and attenuate red meat-induced DNA damage (5, 11, 22, 38). In this 
human study, supplementation with butyrylated resistant starch significantly raised faecal 
butyrate levels. The study identified a novel mechanism by which resistant starch can be 
beneficial for bowel health, with some of the miRNAs that were elevated in rectal tissue with 
the HRM diet alone reduced and restored to baseline levels with resistant starch 
supplementation. In particular, miR-17-92 miRNA levels were significantly lower when the 
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red meat diet was supplemented with resistant starch. miR-21 and miR-16 levels remained 
similar in the red meat diets irrespective of resistant starch supplementation. The persistent 
elevation of miR-21 with red meat intake warrants further investigation to determine any 
impact on CRC risk. 
 
As miRNAs can simultaneously target hundreds of mRNAs, even small expression changes 
can have important cellular effects (39). miR-17-92 and miR-21 promote proliferation (18, 
29, 30, 34, 35), and examination of target gene expression and cell proliferation provided 
preliminary evidence regarding the possible influence of detected miRNA changes on cellular 
function. The increased miR-17-92 miRNA levels with the HRM diet were associated with a 
decrease in mRNA levels of target genes, particularly the cell cycle inhibitor CDKN1A. 
Through target gene regulation, the increase in miR-17-92 miRNAs and miR-21 with the 
HRM diet may contribute to the corresponding increase in cell proliferation. Resistant starch 
supplementation appeared unable to completely restore proliferation to baseline, which could 
be associated with the miR-21 levels that remained elevated compared with the entry diet. 
Other regulatory factors, including other miRNAs, may also be involved. It should be noted 
that the length of the washout period may have been insufficient for these outcomes; 
proliferation after the washout was significantly higher than after the entry diet, for example, 
indicating a potential carry-over effect. High variability in mRNA levels also limits the 
ability to draw firm conclusions from these data, and a larger sample size may have been 
needed for this outcome.  
 
Another study limitation is the identification of correlations that do not necessarily have 
cause-and-effect relationships; for instance, it is unclear what component of red meat is 
increasing miR-17-92 and miR-21 levels. Haem iron, for example, has been associated with 
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altered gene expression and hyperproliferation of colonic epithelium (40), and haem can also 
play a role in miRNA processing (41); however, any dietary haem uptake is likely limited to 
surface epithelial cells (40). High fat or high cholesterol diets can also alter miRNA 
expression in liver cells (42). It is also not conclusively determined what aspect of the 
resistant starch is protective. As butyrylated resistant starch was used, this is likely to have 
directly administered further butyrate to the colon; butyrylated resistant starch can also be 
more effective in reducing carcinogen damage than standard resistant starch (23, 43). 
Offering support for the hypothesis that the miRNA changes with resistant starch 
supplementation may be due to increased butyrate production, is the in vivo replication of in 
vitro findings from previous work where the miR-17-92 cluster but not miR-21 or miR-16 
responded to butyrate treatment (18).  
 
An important difference between this study and previous in vitro work was that it was 
performed in volunteers with normal rectal mucosa, rather than in CRC cells. Butyrate is a 
preferred energy source for normal colonic epithelium and assists in normal proliferation; 
while alternative fuel sources are preferred in CRC cells, and butyrate instead can inhibit 
proliferation and induce differentiation or apoptosis (9, 44, 45). Observations in carcinogen-
treated rats showed that the colon cells responded to high butyrate levels in a manner more 
similar to cancer cells, with decreased proliferation and enhanced apoptosis (11, 38). In this 
study, there was a similar regulation of the miR-17-92 cluster by butyrate in healthy rectal 
cells in vivo, as previously shown in CRC cells in vitro. This was observed in the context of 
high red meat, with resistant starch restoring miRNA levels to those of the entry diet. While 
there was no significant carry-over effect at the end of the washout period for any miRNA 
measured, for participants who had the HRM diet first, it is possible that residual red meat 
effects at the start of the washout period may have reduced the extent to which the resistant 
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starch decreased miR-17-92 miRNA levels, potentially leading to an under-representation of 
the degree of attenuation.  
 
This study presents the first evidence in humans that high red meat and butyrylated resistant 
starch have opposing effects on miRNA levels in rectal mucosa. Several studies have 
examined the effect of dietary components in other in vivo models. Examination of the 
miRNA response in rats fed diets containing corn or fish oil with pectin or cellulose and 
injected with a carcinogen or saline control particularly demonstrated a novel role for fish oil 
in protecting the colon from carcinogen-induced miRNA dysregulation, rather than a role for 
fibre (46, 47). Shah et al (2011) did however demonstrate that various dietary combinations 
and carcinogen exposure modulated a number of miRNAs, including miR-17-92 cluster 
miRNAs and miR-21 (47). 
 
The oncogenic miR-17-92 cluster was shown to be differentially regulated by dietary factors 
that increase or decrease CRC risk, and this may explain, at least in part, the respective risk 
profiles of high red meat and resistant starch. Although the HRM diet increased miR-17-92 
cluster miRNA levels in rectal mucosa, with downstream consequences, addition of 
butyrylated resistant starch to the HRM diet restored miR-17-92 levels to baseline. While the 
red meat intake during the trial may exceed levels consumed by many in the general 
population, red meat intake in developed countries is substantial. Total meat consumption in 
the USA, European Union, and the developed world has continued to increase from 1961 to 
2003; nearly doubling in the EU and increasing 1.5-fold in the USA (48). In the USA, per 
capita total loss-adjusted meat consumption in 2004 was 154 g per day (48). The quantity of 
resistant starch used in the trial could be realistically applied to the general population. Long 
term resistant starch supplementation in select populations has been shown to be feasible 
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(49), and there has been a recent expansion in commercially available foods with increased 
resistant starch content (50). The findings in this study support increased resistant starch 
consumption as a means of reducing risk associated with an HRM diet. 
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FIGURES 
 
 
Fig 1: CONSORT diagram of participant flow for the high red meat and resistant 
starch trial  
HRM: red meat diet; HRM+HAMSB: red meat and resistant starch diet.   
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Fig 2: Faecal butyrate, acetate, propionate, and total SCFA levels of participants in the 
high red meat and resistant starch trial  
Faecal samples collected at the end of each four-week diet (* P < 0.05, ** P < 0.01, *** P < 
0.001). The mean ± SEM of the 23 participants is shown for each diet. Entry: entry diet; 
HRM: red meat diet; HRM+HAMSB: red meat and resistant starch diet. 
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Fig 3: miR-17-92, miR-16 and miR-21 levels in rectal biopsies from participants in the 
high red meat and resistant starch trial  
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Rectal biopsies collected at the end of each four-week diet (* P < 0.05, ** P < 0.01). 
Expression measured by real-time RT-PCR and normalised to RNU6B levels. (A) miR-17-92 
miRNA levels shown for each diet. (B) Summary of miR-17-92 levels for the intervention 
diets, presented as percent change from entry diet. (C) miR-16 and miR-21 levels shown for 
each diet. The mean ± SEM of the 23 participants is shown for each diet. Entry: entry diet; 
HRM: red meat diet; HRM+HAMSB: red meat and resistant starch diet. 
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Fig 4: Gene expression and cell proliferation in rectal biopsies from participants in the 
high red meat and resistant starch trial  
Rectal biopsies collected at the end of each four-week diet (* P < 0.05). (A) CDKN1A, PTEN, 
and BCL2L11 mRNA levels shown for each diet. mRNA levels measured by real-time RT-
PCR and normalised to ACTB and B2M levels. (B) Cell proliferation shown for each diet, 
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measured by proliferating cell nuclear antigen (pCNA) assay. (C) Cell proliferation by 
treatment group (Group 1 had HRM diet first, Group 2 had HRM+HAMSB diet first). The 
mean ± SEM of the 23 participants is shown for each diet. Entry: entry diet; HRM: red meat 
diet; HRM+HAMSB: red meat and resistant starch diet. 
 
 
 
 
